Prof. Chan SY, Dr. Thomas B from the Divisions of Cardiovascular Medicine and Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA, has published a research paper in the 24 June 2014 J Clin Invest. (I.F: >15) stating that “Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.” This study provides mechanistic insights into how miR-130/301 promotes Pulmonary pathogenesis.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Molecular therapy for Hypertension: Prostaglandin-E2 (PGE2) inhibits pulmonary hypertension via up regulation of its target genes. This study suggests that pharmacological formulations encompassing “PGE2 or its analogues” may be used to treat pulmonary hypertension.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Hypertension: Prostaglandin-E2 (PGE2) inhibits pulmonary hypertension via up regulation of its target genes, 25/July/2014, 5.19 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
